COMMUNIQUÉS West-GlobeNewswire

U.S. FDA grants Priority Review for Roche’s Enspryng for MOGAD, an autoimmune disease with no approved treatments
10/09/2026
If approved, Enspryng would be the first and only disease-modifying therapy for MOGAD (myelin oligodendrocyte glycoprotein antibody-associated disease) Filing acceptance is based on the Phase III METEOROID study showing [...]
VVMF, Australia's First Viral Vector CDMO Receives TGA Manufacturing Licence
10/09/2026
Regulatory milestone strengthens Australia’s sovereign advanced therapeutics manufacturing capability SYDNEY, Sept. 10, 2026 (GLOBE NEWSWIRE) -- Viral Vector Manufacturing Facility Pty Ltd (VVMF), Australia’s first [...]
Hexiris Ophthalmics to Present First-in-Human OBi Glaucoma Data at Five Fall Meetings, Beginning with the Ophthalmology Futures Forum in London
10/09/2026
Physician-founded company will bring its office-based interventional glaucoma platform to Ophthalmology Futures, ESCRS, Sally Letson, CGS and AAO 2026 DIEPPE, New Brunswick, Sept. 10, 2026 (GLOBE NEWSWIRE) -- Hexiris [...]
CONNECTA Therapeutics Announces Financing to Advance Clinical Development of Fragile X Syndrome Program
10/09/2026
€3.1 million financing led by new investor Clave Capital, with participation from existing investors Proceeds will support completion of ongoing Phase IIa trial of CTH120 in Fragile X syndrome, with topline data readout [...]
Disc Medicine Presents Initial Results from RESTORE-PV Phase 2 Trial in Patients with Polycythemia Vera (PV) at the 14th Society of Hematologic Oncology (SOHO) Annual Meeting
10/09/2026
Initial results from RESTORE-PV show DISC-3405 increased hepcidin and lowered serum iron, translating to controlled hematocrit, reduced phlebotomy, and improved symptoms in PV patients DISC-3405 is the first monoclonal [...]
Zoher F. Kapasi, PhD, PT, Named Provost of Thomas Jefferson University
09/09/2026
PHILADELPHIA, Sept. 09, 2026 (GLOBE NEWSWIRE) -- Thomas Jefferson University has announced the appointment of Zoher F. Kapasi, PhD, PT, as its next Provost effective Nov. 1, 2026. With extensive experience in higher [...]
Oruka Therapeutics to Attend the 2026 Morgan Stanley Global Healthcare Conference
09/09/2026
MENLO PARK, Calif., Sept. 09, 2026 (GLOBE NEWSWIRE) -- Oruka Therapeutics, Inc. (“Oruka”) (Nasdaq: ORKA), a clinical-stage biotechnology company developing novel biologics designed to set a new standard for the [...]
First Infant Data from Ascendis Trial of Once-Weekly TransCon CNP (Navepegritide) Presented at ESPE 2026
09/09/2026
– Achondroplasia Foramen Magnum Score was stable or improved between baseline and Week 52 with TransCon CNP treatment – Treatment with TransCon CNP increased linear growth in the sentinel cohort, with an improvement in [...]
Genelux Announces Publication of a Deep and Durable Response in a Platinum-relapsed Small Cell Lung Cancer Patient Following Systemically Delivered Olvi-Vec-Primed Immunochemotherapy
09/09/2026
-- A platinum-relapsed SCLC patient achieved 16.7 months progression-free survival following Olvi-Vec and platinum rechallenge, exceeding the PFS achieved following platinum-based first-line therapy -- -- This patient [...]
Mineralys Therapeutics Reports Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)
09/09/2026
RADNOR, Pa., Sept. 09, 2026 (GLOBE NEWSWIRE) -- Mineralys Therapeutics, Inc. (Nasdaq: MLYS), a biopharmaceutical company focused on developing medicines to target hypertension and aldosterone-related adverse outcomes in [...]
MacroGenics to Participate in the H.C. Wainwright 28th Annual Global Investment Conference
09/09/2026
ROCKVILLE, MD, Sept. 09, 2026 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (Nasdaq: MGNX), a biopharmaceutical company focused on developing innovative antibody-based therapeutics for the treatment of cancer, today announced [...]
Century Therapeutics Appoints Joseph Truitt to Board of Directors
09/09/2026
PHILADELPHIA, Sept. 09, 2026 (GLOBE NEWSWIRE) -- Century Therapeutics, Inc. (‘Century’, NASDAQ: IPSC), a biotechnology company developing induced pluripotent stem cell (iPSC)-derived cell therapies for autoimmune [...]
CooperCompanies Completes Strategic Review, Increases Share Repurchase Authorization
09/09/2026
Board Unanimously Concludes to Retain CooperSurgical Expands Share Repurchase Authorization from $2 billion to $3 billion Board Remains Open to All Value Options that Create Shareholder Value SAN RAMON, Calif., Sept. 09 [...]
NANOBIOTIX Participera à la Conférence H.C. Wainwright 28th Annual Global Investment
09/09/2026
PARIS and CAMBRIDGE, Mass., 09 sept. 2026 (GLOBE NEWSWIRE) -- NANOBIOTIX (Euronext : NANO – NASDAQ : NBTX – la « Société »), société française de biotechnologie en phase de développement clinique avancé, pionnière des [...]
NANOBIOTIX to Participate in the H.C. Wainwright 28th Annual Global Investment Conference
09/09/2026
PARIS and CAMBRIDGE, Mass., Sept. 09, 2026 (GLOBE NEWSWIRE) -- NANOBIOTIX (Euronext: NANO - NASDAQ: NBTX - the “Company”), a late-stage clinical biotechnology company pioneering physics-based approaches to expand [...]
Crescent Biopharma Announces Grants of Inducement Awards
09/09/2026
WALTHAM, Mass., Sept. 09, 2026 (GLOBE NEWSWIRE) -- Crescent Biopharma , Inc. (“Crescent” or the “Company”) (Nasdaq: CBIO), a clinical-stage biotechnology company dedicated to rapidly advancing the next wave of therapies [...]
CooperCompanies Announces Third Quarter 2026 Results
09/09/2026
SAN RAMON, Calif., Sept. 09, 2026 (GLOBE NEWSWIRE) -- CooperCompanies (Nasdaq: COO), a leading global medical device company, today announced financial results for its fiscal third quarter ended July 31, 2026. Revenue [...]
Venus Concept Announces CEO Transition
09/09/2026
TORONTO, Sept. 09, 2026 (GLOBE NEWSWIRE) -- Venus Concept Inc. (“Venus Concept” or the “Company”), a global medical aesthetic technology leader, today announced the appointment of Brad Oliver as Chief Executive Officer [...]
Actuate to Present at the H.C. Wainwright 28th Annual Global Investment Conference
09/09/2026
CHICAGO and FORT WORTH, Texas, Sept. 09, 2026 (GLOBE NEWSWIRE) -- Actuate Therapeutics, Inc. (NASDAQ: ACTU) (“Actuate” or the “Company”), a clinical-stage biopharmaceutical company, focused on developing therapies for [...]

Pages